A groundbreaking trial of an interactive digital therapy designed to train individuals to alter their own brain waves has demonstrated significant potential as a treatment for chronic nerve pain. This innovation offers a glimmer of hope for patients and clinicians alike, who have long sought a new generation of drug-free treatments to combat the debilitating effects of neuropathic pain without the risks and side effects associated with traditional pharmaceutical interventions like opioids.
The technology, known as "PainWaive," is the result of years of rigorous research by a team at UNSW Sydney. It is designed to teach users how to regulate abnormal brain activity that is fundamentally linked to chronic nerve pain. By providing a potential in-home, non-invasive alternative to opioid-based pain management, the researchers hope to change the landscape of chronic care.
A recent pilot study of the technology, led by Professor Sylvia Gustin and Dr. Negin Hesam-Shariati from UNSW Sydney’s NeuroRecovery Research Hub, has yielded highly encouraging results. These findings were recently published in the Journal of Pain, signaling a shift in how medical science may soon approach the management of chronic sensory conditions.
The study employed a comprehensive assessment method, tracking hundreds of individual metrics across participants. Researchers monitored pain levels and secondary complications, such as pain interference in daily life, before, during, and after a four-week period of intensive interactive game play. To ensure accuracy, brain activity was monitored via specialized EEG (electroencephalogram) headsets. The PainWaive app was engineered to respond in real time to subtle shifts in the user’s brainwave patterns, providing immediate biofeedback that allows the user to learn how to self-regulate their neurological state.
The outcomes of the initial trial were striking. Three out of the four participants demonstrated significant, measurable reductions in their chronic pain levels, with the most profound improvements occurring as they approached the end of the four-week treatment cycle. Perhaps most significantly, the level of pain relief achieved by these participants was found to be comparable to, or in some instances, greater than the relief typically provided by traditional opioid-based medications.
Despite the optimism surrounding these results, the research team remains cautious and scientific in their appraisal. Dr. Hesam-Shariati emphasizes that while the data is compelling, the study’s small sample size, specific design, and relatively short duration mean that the findings cannot yet be generalized to the broader population. Furthermore, while the results are promising, the team is working toward future studies that will allow them to definitively rule out the potential for placebo effects.
"The results we’ve seen are exciting and give us confidence to move to the next stage and our larger trial," Dr. Hesam-Shariati notes. The team is already looking ahead, using the data gathered from this pilot to refine their protocols and improve the efficacy of the system for a wider demographic.
The PainWaive project is not an isolated development; it is the culmination of years of seminal research conducted by Professor Sylvia Gustin into the neurobiology of pain. Specifically, her work focuses on structural and functional changes in the brain’s thalamus—the central relay station responsible for transmitting sensory information throughout the brain—which is frequently associated with neuropathic pain.
Professor Gustin explains that the brainwaves of individuals suffering from chronic nerve pain exhibit a distinct, identifiable signature. "The brainwaves of people with neuropathic pain show a distinct pattern: more slow theta waves, fewer alpha waves, and more fast, high beta waves," she observes. "We believe these changes interfere with how the thalamus talks to other parts of the brain, especially the sensory motor cortex, which registers pain."
This insight led to a critical, clinical question: Could a treatment be developed that directly targets these specific wave patterns to "normalize" them? The resulting interdisciplinary effort, which brought together experts from UNSW Science and Neuroscience Research Australia (NeuRA), successfully translated this theoretical framework into the practical application now known as PainWaive.
In the first trial, the logistics of the treatment were designed to be as user-friendly as possible. Each of the four participants was provided with a kit containing an EEG headset and a tablet preloaded with the PainWaive app. The app provided clear, actionable directions for use. To aid in the regulation of their brain waves, participants were taught specific mental strategies—such as practicing mindfulness, relaxation techniques, or focusing on positive, happy memories—which helped guide their brain activity toward a more "normal" state. Throughout the process, the system automatically uploaded user data to the research team, allowing for continuous, remote monitoring without the need for constant clinical visits.
The independence afforded to the patients was a standout feature of the study. Dr. Hesam-Shariati highlights that after only a couple of guided sessions via Zoom, participants were fully capable of running the treatment protocols on their own. This autonomy is vital, as it allows patients to feel empowered to manage their pain within the comfort and familiarity of their own home environment. This shift from clinical reliance to patient self-management is a core component of what makes this technology so unique in the current medical landscape.
The development of the technology itself presented significant hurdles. Initially, the research team intended to utilize existing commercial EEG systems to facilitate the training. However, they quickly discovered that available off-the-shelf systems were either prohibitively expensive or failed to meet the rigorous technical standards required to deliver the quality of data necessary for the project. In response, the team pivoted to building their own custom hardware.
According to Dr. Hesam-Shariati, almost every component of the system—with the exception of the open-source EEG board—was built in-house. Even that, he notes, is slated for replacement by a custom-designed board in the near future. This hands-on approach allowed the researchers to maintain total control over the technology’s performance.
Cost-efficiency was another major driver of the team’s design choices. By utilizing advanced 3D printing technology, Professor Gustin and her team were able to drastically reduce the cost of each headset to approximately $300. This is a massive improvement over existing clinical systems, which often carry price tags ranging from $1,000 to as much as $20,000.
To ensure the signal quality remained high enough to provide accurate feedback to the brain, the headset utilizes a saline-based wet electrode system that specifically targets the sensorimotor cortex. Professor Gustin notes that the team prioritized patient comfort throughout the design process, working closely with volunteers to ensure the device was lightweight, ergonomic, and truly user-friendly.
The ultimate vision for the team is accessibility. By owning the underlying technology, the researchers hope to eventually offer PainWaive as a genuinely affordable solution for at-home pain management. This is particularly important for patients who have limited access to traditional, high-cost healthcare or specialized pain clinics.
Building on the momentum of this initial success, the researchers are now preparing for the next phase of their work. They are currently calling for volunteers to participate in two upcoming, more extensive trials of the neuromodulation technology. The first, the "Spinal Pain Trial," will investigate the potential for PainWaive to reduce chronic spinal pain, while the second, the "StoPain Trial," will specifically explore the technology’s application in treating chronic neuropathic pain in individuals living with spinal cord injuries. As the research continues, the team hopes to provide robust evidence that these interactive games are more than just a novelty—they could be a transformative tool in the management of chronic pain.
